PATENT COOPERATION TREATY

	From the INTERNATIONAL BUREAU		
PCT	To:		
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis.1 and Administrative Instructions, Section 422) Date of mailing (day/month/year) 18 février 2002 (18.02.02)	PRIVETT, Kathryn, Louise SmithKline Beecham Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS ROYAUME-UNI		
Applicant's or agent's file reference FB/B45197	IMPORTANT NOTIFICATION		
International application No. PCT/EP00/08728	International filing date (day/month/year) 06 septembre 2000 (06.09.00)		
The following indications appeared on record concerning: the applicant the inventor	X the agent the common representative		
Name and Address PRIVETT, Kathryn, Louise	State of Nationality State of Residence		
SmithKline Beecham Two New Horizons Court Brentford Middlesex TW8 9EP	Telephone No. +44 20 8975 2585		
United Kingdom	Facsimile No. +44 181 975 6294		
	Teleprinter No.		
2. The International Bureau hereby notifies the applicant that the person the name X the add			
Name and Address PRIVETT, Kathryn, Louise	- State of Nationality State of Residence		
SmithKline Beecham Corporate Intellectual Property (CN9.25.1)	Telephone No. +44 20 8047 5000		
980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom	Facsimile No. +44 20 8047 6894		
Officed Kingdom	Teleprinter No.		
3. Further observations, if necessary: Please note that address of agent Chapter II has	been changed as above too.		
4. A copy of this notification has been sent to:			
X the receiving Office	the designated Offices concerned		
the International Searching Authority the International Preliminary Examining Authority	the elected Offices concerned other:		
	Authorized officer		
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Alexandre BOUVIER		
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38		

PATENT COOPERATION TREATY

PCT

REC'D 28 NOV 2001

WIPO REPOR FOT

INTERNATIONAL PRELIMINARY EXAMINATION

(PCT Article 36 and Rule 70)

14

			, (
Applicant's FB/B451	or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)		
		International filing date (day/moni			
PCT/EPC	al application No.	06/09/2000	07/09/1999	,	
		national classification and IPC			
A61K39/		national classification and in C			
					
Applicant					
SMITHK	INE BEECHAM BIOLO	GICALS S.A. et al.			
1. This i	nternational preliminary ex	amination report has been prepare	by this International Preliminary	Examining Authority	
	transmitted to the applica				
2. This I	REPORT consists of a total	of 5 sheets, including this cover	neet.		
⊠ T	his report is also accompa	nied by ANNEXES, i.e. sheets of t basis for this report and/or sheets	e description, claims and/or draw	ings which have	
(9	see Rule 70.16 and Section	n 607 of the Administrative Instruc	ons under the PCT).	no tino ridinonty	
·					
These	e annexes consist of a tota	l of 3 sheets.			
3. This	enort contains indications i	relating to the following items:			
0		coming as and some many manner			
1	☑ Basis of the report				
11	☐ Priority				
III		of opinion with regard to novelty, in	entive step and industrial applica	bility	
IV	☐ Lack of unity of inve			al applicability	
V		t under Article 35(2) with regard to ations suporting such statement	noverty, inventive step or industria	агаррисаршту;	
VI	□ Certain documents	_			
VII	☑ Certain defects in th	e international application			
VIII	☐ Certain observation	s on the international application			
Date of out	omission of the demand	Date	completion of this report		
Date of Sul	minesion of the demand	Dale	completion of the report		
28/03/20	01	27.11.	001		
	mailing address of the internat	onal Author	zed officer	STANDED MATURE	
preliminary	examining authority: European Patent Office - P.E	3. 5818 Patentiaan 2			
ചി	NL-2280 HV Rijswijk - Pays	Bas Sitch	W		
<u>*</u>	Tel. +31 70 340 - 2040 Tx: 3	31 651 epo nl	nno Nio 104 70 040 0040	TO TO SOURCE TO	

Telephone No. +31 70 340 3040



I. Basis of the report

١.	the and	receiving Office in	ments of the international a response to an invitation u o this report since they do	ınder Article 14 are	referred to in this	report as "originally file	
	1-32	2	as originally filed				
	Clai	ims, No.:					
	1-18	3	as received on	01/11/2001	with letter of	22/10/2001	
	Dra	wings, No.:					
	1/10	0-10/10	as originally filed				
2.	With lang	n regard to the lang guage in which the	guage, all the elements ma international application w	arked above were a as filed, unless othe	vailable or furnisl erwise indicated u	ned to this Authority in thunder this item.	he
	The	se elements were	available or furnished to th	is Authority in the fo	ollowing language	e: , which is:	
		the language of a	translation furnished for th	e purposes of the i	nternational sear	ch (under Rule 23.1(b)).	
		the language of po	ublication of the internatior	nal application (und	er Rule 48.3(b)).		
		the language of a 55.2 and/or 55.3).	translation furnished for th	e purposes of inter	national prelimina	ary examination (under l	Rule
3.			cleotide and/or amino ac ry examination was carried				
		contained in the ir	nternational application in v	written form.			
		filed together with	the international application	on in computer read	dable form.		
		furnished subsequ	uently to this Authority in w	ritten form.			
		furnished subsequ	uently to this Authority in c	omputer readable f	orm.		
			at the subsequently furnish application as filed has bee		e listing does not	go beyond the disclosu	ıre in
		The statement that listing has been fu	at the information recorded urnished.	in computer reada	ble form is identic	cal to the written sequen	ice
4.	The	amendments have	e resulted in the cancellation	on of:			
		the description,	pages:				

Nos.:

☐ the claims,

		the drawings,	sheets:				
5.		☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):					
		(Any replacement she report.)	eet contair	ning such	amendments must be referred to under item 1 and annexed to this		
6.	Add	itional observations, if	necessar	y:			
٧.		soned statement und tions and explanation			rith regard to novelty, inventive step or industrial applicability; ch statement		
1.	Stat	ement					
	Nov	elty (N)	Yes: No:	Claims Claims	1-18 None		
	Inve	entive step (IS)	Yes: No:	Claims Claims	1-18 None		
	Indu	ıstrial applicability (IA)	Yes: No:	Claims Claims	1-18 None		

2. Citations and explanations see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted: see separate sheet

INTERNATIONAL PRELIMINARY **EXAMINATION REPORT - SEPARATE SHEET**

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The argumentation of the applicant put forward during these proceedings has been taken into account.

Claim 1 now disclaims the presence of an HSV antigen in the vaccine composition. The earlier patent application filing by the same applicant, published as WO9945957, and the subject matter of the present application clearly relate to different inventions, and the priority claimed in respect of the present application is considered valid. Accordingly, the earlier filing, WO9945957, is of no relevance to the present proceedings.

Reference is made to the following documents:

D1: Virology, 200, 1994, 547-557

D2: WO9517209

1. Novelty (Art. 33(2) PCT).

The claims of the application are novel in light of the available prior art.

2. Inventive Step (Art. 33(3) PCT)

Closest prior art for the assessment of inventive step, D1. This discloses chimaeric Hepatitis B core antigen particles, expressing HPV E7 epitopes. Induction of antibody immune response to the HPV B epitopes, and T cell immune response to HPV T epitope and HBV T epitopes was achieved upon delivery in mice. See page 547, abstract; page 547, para. 1 - page 548, para. 2; figure 1; page 556, para. 4, thereof. Difference between claim 1 and D1, incorporation of an adjuvant which is a preferential stimulator of TH1 cell response.

Problem to be solved: provision of HBV-HPV vaccine compositions whereby the immune response generated (for example the isotypic profile of the response) to each antigen in the composition is essentially the same as that obtained by each antigen given individually.

In addressing this problem, whilst it may be considered that the skilled person would be motivated to attempt to solve this problem by incorporating a known TH1 type adjuvant

INTERNATIONAL PRELIMINARY **EXAMINATION REPORT - SEPARATE SHEET**

(as disclosed for example in D2, page 1, line 24 - page 5, line 16) in a vaccine of the type disclosed in D1, there would nevertheless appear no reason, either in light of the available prior art, or in light of his own technical knowledge, for the skilled person to reasonably expect that this problem may be successfully solved in this way. Accordingly, inventive step for claim 1, and thus claims 2- 18 also, may be acknowledged.

3. For the assessment of the present claims 1-18 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

Application No	Publication date (day/month/year)	Filing date	Priority date (valid claim)
Patent No		(day/month/year)	(day/month/year)
WO0117551	15-3-2001	7-9-2000	7 - 9-1999

The above document may be considered prejudicial to the patentability of the subject matter of the present application during later proceedings.

Re Item VII

Certain defects in the international application

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor are these documents identified therein.





From the INTERNATIONAL SEARCHING AUTHORITY

SMITHKLINE BEECHAM Attn. PRIVETT, Kathryn Louise Two New Horizons Court Brentford

NEW HORIZONS COURT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

Middlesex TW8 9EP UNITED KINGDOM	(PCT Rule 44.1)
·	Date of mailing (day/month/year) 11/05/2001
Applicant's or agent's file reference	
FB/B45197	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No.	International filing date (day/month/year) 06/00/2000
PCT/EP 00/08728	06/09/2000
Applicant SMITHKLINE BEECHAM BIOLOGICALS S.A. et a	1.
The applicant is hereby notified that the International Search Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim When? The time limit for filing such amendments is normal International Search Report; however, for more detailed.	ns of the International Application (see Rule 46):
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41–22) 740.14.35 For more detailed instructions, see the notes on the acco	
The applicant is hereby notified that no International Search Article 17(2)(a) to that effect is transmitted herewith.	n Report will be established and that the declaration under
	onal fee(s) under Rule 40.2, the applicant Is notified that: n transmitted to the International Bureau together with the test and the decision thereon to the designated Offices.
no decision has been made yet on the protest; the app	olicant will be notified as soon as a decision is made.
4. Further action(s): The applicant is reminded of the following:	
Shortly after 18 months from the priority date, the international a lf the applicant wishes to avoid or postpone publication, a notice priority claim, must reach the International Bureau as provided completion of the technical preparations for international publications.	e of withdrawal of the international application, or of the in Rules 90 <i>bis.</i> 1 and 90 <i>bis.</i> 3, respectively, before the
Within 19 months from the priority date, a demand for internation wishes to postpone the entry into the national phase until 30 mg	nal preliminary examination must be filed if the applicant on the priority date (in some Offices even later).
Within 20 months from the priority date, the applicant must perfo befor all designated Offices which have not been elected in the priority date or could not be elected because they are not bound	e demand or in a later election within 19 months from th

Nam and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Authorized officer

Geertruida Groeneveld-Van der Spek



These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international politication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended, it must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	(Form PCT/ISA/2	of Transmittal of International Search Report (20) as well as, where applicable, item 5 below.
FB/B45197	ACTION	,,,,
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/EP 00/08728	06/09/2000	07/09/1999
Applicant		
SMITHKLINE BEECHAM BIOLOG	ICALS S.A. et al.	
This International Search Report has been	n prepared by this International Searching Auth	nority and is transmitted to the applicant
according to Article 18. A copy is being tra	ansmitted to the International Bureau.	
	3	
This International Search Report consists It is also accompanied by	of a total of sheets. a copy of each prior art document cited in this	rapart
it is also accompanied by	a copy of each phor art document died in this	тероп.
1. Basis of the report		
With regard to the language, the language in which it was filed, unl	international search was carried out on the bases otherwise indicated under this item.	sis of the international application in the
the international search w	as carried out on the basis of a translation of t	he international application furnished to this
Authority (Rule 23.1(b)). b. With regard to any nucleotide an was carried out on the basis of the	d/or amino acid sequence disclosed in the in	nternational application, the international search
	onal application in written form.	
filed together with the inte	ernational application in computer readable form	m.
furnished subsequently to	this Authority in written form.	
furnished subsequently to	this Authority in computer readble form.	
	osequently furnished written sequence listing d is filed has been furnished.	loes not go beyond the disclosure in the
the statement that the info	ormation recorded in computer readable form is	s identical to the written sequence listing has been
2. Certain claims were fou	nd unsearchable (See Box I).	
3. Unity of invention is lac	king (see Box II).	
4. With regard to the title,		
the text is approved as su	• • • • • • • • • • • • • • • • • • • •	
	hed by this Authority to read as follows:	
VACCINE AGAINST HBV AN	ID HPV	
E Mills and and the state of th		
5. With regard to the abstract,	the state of the analysis	
the text is approved as su the text has been establis within one month from the	iomitted by the applicant. Thed, according to Rule 38.2(b), by this Authori Adate of mailing of this international search r	ty as it appears in Box III. The applicant may, port, submit comments to this Authority.
6. The figure of the drawings to be publ	•	
as suggested by the appli		Non of th figures.
because the applicant fail		[A] Non Oran ilgures.
	characterizes the invention.	
. Decause this light better	ona ascrizes at all vertuott.	

International Application No P P 00/08728

A. CLASSII	FICATION OF SU	BJECT M	ATTER	
IPC 7	A61K39/	295	A61P31	/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7-A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Α	TINDLE ROBERT W ET AL: "Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice." VIROLOGY, vol. 200, no. 2, 1994, pages 547-557, XP002166056 ISSN: 0042-6822 page 547 abstract page 547, paragraph 1 -page 548, paragraph 2 figure 1	1
	page 556, paragraph 4 _/	

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
25 April 2001	11/05/2001
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Sitch, W

1



P 00/08728

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 17209 A (SMITHKLINE BEECHAM BIOLOG; MOMIN PATRICIA MARIE (BE); GARCON NATHA) 29 June 1995 (1995-06-29) cited in the application page 1, line 24 -page 5, line 16	
A	WO 95 17210 A (SMITHKLINE BEECHAM BIOLOG; MOMIN PATRICIA MARIE (BE); GARCON NATHA) 29 June 1995 (1995-06-29) cited in the application page 1, line 24 -page 5, line 16	
A	WO 94 21292 A (SMITHKLINE BEECHAM BIOLOG; HAUSER PIERRE (BE); VOET PIERRE (BE); S) 29 September 1994 (1994-09-29) page 1, line 26 -page 7, line 2 page 19 -page 10; examples 7,8	
A	WO 93 19780 A (SMITHKLINE BEECHAM BIOLOG; GARCON JOHNSON NATHALIE MARIE (BE); HAU) 14 October 1993 (1993-10-14) page 3, line 19 -page 6, line 22	r-
A	WO 92 11291 A (SMITHKLINE BEECHAM BIOLOG) 9 July 1992 (1992-07-09) page 2, line 19 -page 3, line 31 page 13, line 16 - line 27	
P,X	WO 99 45957 A (SMITHKLINE BEECHAM BIOLOG;STEPHENNE JEAN (BE); WETTENDORFF MARTIN) 16 September 1999 (1999-09-16) page 3, line 12 -page 15, line 31	1-20
E	WO 01 17551 A (SMITHKLINE BEECHAM BIOLOG; WETTENDORFF MARTINE ANNE CECIL (BE)) 15 March 2001 (2001-03-15) page 4, line 4 -page 16, line 28	1-20
•		
		*
· .		
•		

International Application No en on patent family members P 00/08728 Patent document Publication Patent family Publication cited in search report date member(s) date WO 9517209 Α. 29-06-1995 AT 15-03-1999 177322 T ΑU 1316495 A 10-07-1995 AU 687494 B 26-02-1998 1316695 A AU 10-07-1995 ΑU 705521 27-05-1999 AU 6803198 09-07-1998 705519 B AU 27-05-1999 AU 6803298 A 09-07-1998 CA 2179779 A 29-06-1995 CN 1138298 A 18-12-1996 DE 69417063 D 15-04-1999 DE 69417063 28-10-1999 DK 735898 23-08-1999 WO 29-06-1995 9517210 A EP 0735898 A 09-10-1996 EP 0868918 A 07-10-1998 ES 2129801 T 16-06-1999 GR 3029750 30-06-1999 HK 1012243 12-05-2000 JP 9506887 08-07-1997 NZ 277802 A 27-04-1998 SG 49257 A 18-05-1998 SG 73578 A 20-06-2000 SI 735898 30-06-1999 US 6146632 A 14-11-2000 ZA 9410176 A 17-11-1995 WO 9517210 Α 29-06-1995 AT 177322 T 15-03-1999 AU 1316495 A 10-07-1995 26-02-1998 AU 687494 B AU 1316695 A 10-07-1995 AU 705521 27-05-1999 AU 6803198 09-07-1998 705519 AU 27-05-1999 В AU 6803298 A 09-07-1998 CA 2179779 29-06-1995 Α CN 1138298 A 18-12-1996 DE 69417063 D 15-04-1999 DE 69417063 28-10-1999 DK 735898 T 23-08-1999 WO 9517209 A 29-06-1995 EP 0735898 Α 09-10-1996 EP 0868918 07-10-1998 ES 2129801 T 16-06-1999 GR 3029750 30-06-1999 HK 1012243 A 12-05-2000 JP 9506887 08-07-1997 NZ 277802 A 27-04-1998 SG 49257 18-05-1998 SG 73578 20-06-2000 SI 735898 30-06-1999 T US 6146632 A 14-11-2000 ZA 9410176 A 17-11-1995 WO 9421292 Α. 29-09-1994 AP 515 A 09-08-1996 AT 157882 15-09-1997 AU 685443 B 22-01-1998

AU

11-10-1994

6426494 A

Information on patent family members

Patent document Publication Patent family Publication cited in search report member(s) date date WO 9421292 ΑU Α 705739 B 03-06-1999 AU 7541696 A 13-02-1997 BR 9405957 A 12-12-1995 CA 2157376 A 29-09-1994 CN 1119829 03-04-1996 CZ 9502467 13-03-1996 DE 69405551 16-10-1997 DE 69405551 26-03-1998 Т DK 689454 08-12-1997 EP 0689454 A 03-01-1996 EP 0812593 A 17-12-1997 16-01-1998 ES 2109685 954514 FΙ 22-09-1995 GR 3025483 27-02-1998 HK 1011930 A 23-06-2000 HU 72916 A 28-06-1996 IL 109056 A 15-06-1998 17-09-1996 JP 8508722 T NO 953759 22-09-1995 NZ 263538 A 28-10-1996 PL310598 A 27-12-1995 17-04-1998 SG 48309 Α SK 117395 A 06-11-1996 US 5776468 A 07-07-1998 ZA 9401957 A 31-01-1995 WO 9319780 A 14-10-1993 AP 570 A 29-11-1996 AT 146678 15-01-1997 T AU 3397499 A 19-08-1999 AU 3751693 A 08-11-1993 AU 6445796 A 07-11-1996 CA 2132833 A 14-10-1993 CN 1085805 A 27-04-1994 CZ 9402355 A 15-02-1995 DE 69306940 06-02-1997 DK 633784 20-01-1997 18-01-1995 EP 0633784 16-04-1997 ES 2098029 Τ FI 944442 A 26-09-1994 GR 3022174 31-03-1997 HK 1003218 A 16-10-1998 HU 69931 A 28-09-1995 IL 105161 16-08-1998 JP 7505372 15-06-1995 NO 943571 A 14-11-1994 NZ 249868 A 24-03-1997 RU 2121849 C 20-11-1998 SG 48375 A 17-04-1998 SI 9300149 A 31-12-1993 SK 115294 A 07-06-1995 22-07-1992 WO 9211291 Α 09-07-1992 ΑU 9052091 A ΕP 0563091 A 06-10-1993 JP 6503821 T 28-04-1994 WO 9945957 27-09-1999 A 16-09-1999 AU 3328399 A BR 9908599 A 14-11-2000 EP 1064025 A 03-01-2001

International Application No

P 00/08728

Information on patent family members

P 00/08728

Publication

Patent document cited in search report		Publication date	Patent family memb r(s)	Publication date
WO 9945957	Α		NO 20004487 A	19-10-2000
WO 0117551	Α	15-03-2001	NONE	